Prices for retail drugs across US payers decreased for the first time in years, driven by a drop in generic prices and “little to no growth” in prices for brands.

Health and Human Services Department Deputy Secretary Eric Hargan invites biopharma companies to submit proposals on how to modify or create safe harbors that would be suitable for innovative reimbursement contracts involving prescription drugs.

Survey of US and European payers suggests manufacturers should 'leverage' key opinion leaders trusted by payers to help drive better understanding and acceptance of real world data.